Home
Clinical Trials
Early Detection of Advanced A...

Early Detection of Advanced Adenomas and Colorectal Cancer

Last Updated: 2025-06-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-15

Study Completion Date

2026-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Onset Colorectal Cancer Detection

NCT06342401

Colorectal Cancer Colorectal Neoplasms Colorectal Adenocarcinoma +5 more

RECRUITING

Liquid Biopsy Based Multiomics Study for Colorectal Cancer Early Screening

NCT06258434

Colorectal Cancer Adenomatous Polyps Adenoma +1 more

NOT_YET_RECRUITING

Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

NCT03476122

Colo-rectal Cancer

UNKNOWN

Colorectal Polyps Screening With Low-dose CT Colonoscopy

NCT03064828

Polyps Colorectal Neoplasm

UNKNOWN NA

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

NCT00843375

Colonic Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colorectal cancer (CRC) is a significant global health concern, ranking third in diagnosis and second in mortality. Despite being potentially preventable, it remains a leading cause of cancer-related deaths. Traditional screening methods like fecal immunochemical testing (FIT) have shown benefits in reducing late-stage diagnoses but have not effectively prevented CRC incidence. This is because tests like FIT can effectively detect the cancers, but not the precursor lesions, called adenomas. On the other hand, endoscopy-first approaches offer higher sensitivity for such adenomas and, therefore, lower the risk of developing CRC but face challenges such as invasiveness, cost, and patient compliance.

Non-invasive tests are more appealing to patients than invasive tests and can increase participation rates. Biomarker studies have shown promise, but existing tests lack sensitivity for early-stage CRC and advanced adenomas (AAs). This is likely because they assume the same analyte can detect both CRC and AAs, which may not be accurate due to differences in analyte release and the biological changes that occur during the adenoma-carcinoma sequence.

This study proposes developing an innovative liquid biopsy test tailored for AAs and CRC to address this. An ideal screening test should be minimally invasive, highly sensitive, and cost-effective. This test would optimize patient compliance and resource allocation by detecting both conditions from a single blood draw. More specifically, circulating microRNA (miRNA) analysis shows promise: tests based on cell-free microRNA (cf-miRNA) have demonstrated high sensitivity, while those based on exosome-derived microRNA (exo-miRNA) offer high specificity. Therefore, combining both analytes in a single test could maximize sensitivity and specificity.

This study will develop a non-invasive blood test for AA and CRC in four phases:

1. Genome-wide profiling of cf-miRNA and exo-miRNA and selecting the best candidates for biomarker panels.
2. Utilizing machine learning to identify promising candidates and train algorithms for detecting AAs and CRC separately, based on results from quantitative polymerase chain reaction (qPCR) analysis.
3. Combining these algorithms to create detection signatures for both conditions.
4. Independently validating these signatures using diverse cohorts to ensure broad applicability and compare the effectiveness of the blood assay to standard care through retrospective and prospective studies.

This study aims to develop a highly sensitive, specific, and cost-effective liquid biopsy for early detection of AAs and CRC. Success could transform clinical practice by preventing CRC through early detection of pre-malignant lesions. Innovations include incorporating pre-malignant lesions into screening and combining cf-miRNA and exo-miRNA biomarkers for accuracy. This approach could reduce CRC mortality and incidence and pave the way for new clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Colorectal Neoplasms Colorectal Polyp Colorectal Adenocarcinoma Colorectal Disorders Colorectal Dysplasia Colorectal Cancer Stage I Colorectal Cancer Stage II Colorectal Cancer Stage III Colorectal Cancer Stage IV Colorectal Neoplasms Malignant Colorectal Serrated Adenocarcinoma Colorectal Adenoma With Severe Dysplasia Colorectal Adenoma With Mild Dysplasia Colorectal Adenoma With Moderate Dysplasia Colorectal Adenoma and Carcinoma 1 Colorectal Adenomatous Polyp Colorectal Adenocarcinoma Metastatic in the Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-disease controls (Discovery cohort)

Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.

No interventions assigned to this group

Low-risk Adenoma (Discovery cohort)

Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as all of the following:

* 1 to 4 adenomas at most.
* All adenomas have low-grade dysplasia at most.
* All adenomas are \<10 mm in diameter

No interventions assigned to this group

Advanced Adenoma (Discovery cohort)

Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following:

* 5 or more adenomas.
* One or more adenomas have high-grade dysplasia.
* One or more adenomas are \>10 mm in diameter

No interventions assigned to this group

Colorectal Cancer (Discovery cohort)

Individuals who underwent colonoscopy and were found to have colorectal cancer.

No interventions assigned to this group